Cincinnati

Cincinnati, Ohio 45267

1 studies enrolling now · 15 studies all time

What they study most

C. Diff, C. Difficile, CDI, Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence, Crohn's Disease, Endometriosis, FMT, Fecal Microbiota, Fecal Transplant, Heavy Menstrual Bleeding, PTSD

Studies at this site

• A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis — Recruiting now
• 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients — Stopped early
• A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD — Completed
• Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids — Completed
• Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions — Completed
• Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD — Stopped early
• LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids — Completed
• Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff — Completed
• Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection — Completed
• LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids — Completed
• LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids — Completed
• A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer — Completed
• A Study of TRS01 in Participants With Post-surgical Ocular Inflammation — Completed
• To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease — Stopped early
• 12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients — Completed